{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
desoxycorticosterone acetate
to a specific field?
Status:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Dacuronium is an aminosteroid, acting as a competitive antagonist of nicotinic acetylcholine receptors. In animals, dacuronium worked as a short-acting muscle relaxant with a rapid onset of action. In a clinical trial, dacuronium was markedly less potent than tubocurarine and did not show a rapid recovery from its action.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Cloximate is a non-steroidal anti-inflammatory drug, developed in the Dutch company Philips-Duphar B.V. Research Laboratories in the 1970s. Cloximate acts by inhibition of PGE2 biosynthesis. In preclinical experiments, cloximate showed good inhibitory activities in local exudative tests, in the proliferative and functional aspects of experimental inflammation, as well as in the bradykinin-evoked bronchoconstriction test. Cloximate showed almost no harmful effects on the gastrointestinal mucosa and no influence upon the emptying rate of the stomach. Cloximate was evaluated in double-blind clinical trials, where different formulations were compared with naproxen. Gastrointestinal blood loss increased more in the naproxen group than in the group treated with non-enteric coated cloximate.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:espatropate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Espatropate (UK 88060) is an antagonist of M3 muscarinic receptors. Espatropate is a bronchodilator with anticholinergic activity. It was undergoing preclinical development with Pfizer for the treatment of asthma.
Class (Stereo):
CHEMICAL (ACHIRAL)
Fenabutene controls pituitary activity.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Acebrochol is a neuroactive steroid that may act as a sedative and hypnotic, through the mechanism of altering ligand-gated ion channels and cell surface receptors.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Seglitide (previously known as L363,586 or MK-678), a cyclic, hexapeptide analog of somatostatin-14, is a somatostatin receptor 2 (SSTR2) agonist. This compound was studied in Alzheimer's disease. Besides, it possessed inhibitory actions on rat growth hormone (GH) release and thus could have a role in the treatment of acromegaly. Intravenous and intranasal administration of seglitide to diabetic subjects was effective in reducing both fasting and postprandial hyperglycemia. Thus, this compound could be useful in the control of unstable diabetes. In addition, preclinical studies have shown that seglitide had potential as a treatment for diabetic retinopathy and macular degeneration. However, the further studied of this compound were discontinued.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Rifamexil (also known as MDL 62769 or P/DEA) is a derivative of rifamycin (a natural antibiotic produced by Amycolatopsis rifamycinica). This drug has greater intrinsic activity against Myobacterium avium (MAC) than rifampin. Information on current use of this compound is not available.
Class (Stereo):
CHEMICAL (RACEMIC)
Nisbuterol, a nicotinic acid ester, is a bronchodilator.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Salmisteine was studied as an antipyretic and mucolytic agent. Information about the current use of this compound is not available.
